Pharmacogenomics and Personalized Medicine

Aims and Scope

Editor-in-Chief: Dr Martin H Bluth

Pharmacogenomics and Personalized Medicine is an international, peer-reviewed, open-access journal characterizing the influence of human genotype on pharmacology leading to the development of personalized treatment programs and individualized drug selection for improved safety, efficacy and sustainability.

Pharmacogenomics and Personalized Medicine aims to serve both the academic and industrial communities and accepts research on the following topics:

• Genomic and proteomic profiling
• Genetics and drug metabolism
• Genetic variability in drug toxicity and efficacy
• Genetic-based vaccine development
• Targeted drug identification, discovery and delivery
• Optimizing drug selection and dosage based on patient's genetic profile
• Drug related morbidity and mortality intervention
• Advanced disease screening and targeted therapeutic intervention
• Practical and organizational challenges in the development and implementation of personalized medicine programs
• Patient satisfaction and preference
• Health economic evaluations of personalized medicine

When considering submission of a paper utilizing publicly-available data (e.g. GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria. Animal-only studies will not be considered.

The journal is open to embrace breakthrough research papers so to enhance development of the subject. To increase the diversity of research aspects, the journal aims at various authorship and readership audiences.

The journal welcomes submitted papers covering original research, clinical studies, reviews and evaluations, guidelines, policy papers, expert opinion and commentary, case reports and extended reports.

Pharmacogenomics and Personalized Medicine will no longer consider meta-analyses for publication.

Updated 10 September 2024